Cancer vaccine

Ovarian cancer cells
#Cancer research #Cancer vaccine #CureLab Oncology #DNA #Oncology #Women's health

DNA therapy effective against chemo-resistant ovarian cancer

A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer. The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a… Read More

#Cancer Research #Editor's Choice #News

Business financing
#Cancer immunotherapy #Cancer vaccine #Financing #Immunotherapy #Nouscom #Oncology

Cancer immunotherapy company raises €67.5 million

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalised viral vector-based cancer vaccines, has raised €67.5 million in an oversubscribed Series C financing round. The proceeds will enable Nouscom to advance its pipeline and complete Phase II clinical trials with its cancer vaccine NOUS-209. Representatives from Andera Partners, Bpifrance… Read More

#Business & Investment #News

Vaccine vial and syringe
#Cancer research #Cancer vaccine #DDW Turning Science into Business Summit #Events #Immunology / Virology & Vaccines #Oncology #Webinar

DDW Cancer Research Summit: Insight on cancer vaccines

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. This free summit, sponsored by Taconic Biosciences, will offer expert thought leadership… Read More

#Cancer Research #News

Lungs
#Antibody #Cancer research #Cancer vaccine #IO Biotech #Lung cancer #Merck #Oncology #Phase II trial

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More

#Cancer Research #News

MRI of the brain showing glioblastoma
#Brain cancer #Cancer research #Cancer vaccine #Immunomic Therapeutics #Oncology #Phase I trial

Plasmid DNA vaccine for brain cancer enters Phase I trial

Immunomic Therapeutics has commenced its Phase I clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. ITI-1001 is an investigational plasmid DNA vaccine therapy designed to target the pp65, IE-1 and… Read More

#Cancer Research #News

#Cancer drug targets #Cancer research #Cancer vaccine #Immunotherapy #Lung cancer #Oncology

World Lung Cancer Day: Five drug discovery breakthroughs

This World Lung Cancer Day, DDW’s Diana Spencer takes a look at five 2023 discoveries that could transform the treatment of lung cancer in the near future. Allogeneic cell vaccines In July 2023, Lineage Cell Therapeutics and Cancer Research UK announced encouraging primary and secondary endpoint… Read More

#Cancer Research #News #Trending News

#AACR 2023 #Cancer research #Cancer vaccine #Drug discovery #Oncology

New podcast episode: DDW Highlights

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news stories dominating the headlines this week have been the breaking developments in cancer drug… Read More

#News

#AACR 2023 #Cancer research #Cancer vaccine #Drug discovery #Oncology

This week in drug discovery (16-21 April)

News round-up for 16-21 April by DDW Digital Content Editor Diana Spencer. The news stories dominating the headlines this week have been the breaking developments in cancer drug discovery announced at the American Association of Cancer Research (AACR) Annual Meeting, which was held in Florida, US… Read More

#News

#AACR 2023 #Cancer research #Cancer vaccine #mRNA #mRNA-based vaccines #Oncology

Personalised mRNA cancer vaccine prolongs survival in melanoma

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb… Read More

#Cancer Research #News #Trending News

#Antibiotics #Cancer vaccine #Drug discovery #HIV #Long Covid #Malaria

This week in drug discovery (10-14 April)

News round-up for 10-14 April by DDW Digital Content Editor Diana Spencer. The headlines getting our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. Perhaps most significantly,… Read More

#News

#Antibodies #Cancer research #Cancer vaccine #DDW Highlights podcast #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As March draws to a close, this week’s key announcements have demonstrated the breadth of… Read More

#News

#Antibodies #Cancer research #Cancer vaccine #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

This week in drug discovery (27-31 March)

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer.   As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.  The… Read More

#News

Vaccine vial and syringe
#Cancer research #Cancer vaccine #China #Oncology #Solid tumours #Vaccines

Chinese regulator approves personalised cancer vaccine trial

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. This breakthrough marks the first of its kind in China and represents a significant milestone… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cancer research #Cancer vaccine #National Institute of Allergy and Infectious Diseases #Oncology #T-Cells

Experimental cancer vaccine shows promise in animal studies 

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.    The researchers found that intravenous (IV) administration of the vaccine… Read More

#Cancer Research #News

#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Merck and Moderna to jointly develop personalised cancer vaccine 

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna.   mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk… Read More

#Cancer Research #News

#Cancer #Cancer research #Cancer vaccine #Chemotherapy #Chemotherapy-resistance #Drug resistance #Epigenetics #Oncology #Personalised medicine

Cancer research drugs: Where is the innovation?

An update on the latest oncology developments by DDW Digital Content Editor Diana Spencer The last month has seen huge strides forward in our understanding of cancers, particularly in how they develop resistance to therapies and how we can ‘outsmart’ them using gene editing or different therapeutic pathways, but also… Read More

#Cancer Research #Editor's Choice #News